🥊 NASDAQ: SBFM looking to deliver a TKO in Gains!

[UNSUBSCRIBE]( NEW ALERT: NASDAQ: SBFM Sunshine Biopharma Inc. (NASDAQ: SBFM) is a pharma company to be paying attention to that could have a tremendous reversal back to nearly $10 in its future! Greetings All, The global pandemic has put the spotlight on many pharmaceutical companies in the market for the last two years. Some have seen enormous success. Case in point with Moderna and its vaccine. The pharma market generates around $500 billion a year in revenue. [Americans spent $511 billion on medicine in 2019 alone.]( This makes pharmaceutical companies ones to pay attention to, no matter where the market is at the moment. As the stock market remains volatile amid elevated inflation in 2022, many investors will turn to the pharmaceutical sector for safe-harbor investments because consumers will cut back on nearly any other category before health care during a downturn. Trading now at around $1, one NASDAQ pharma company could see an enormous rebound as it recently hit as high as $9.87! Sunshine Biopharma Inc. (NASDAQ: SBFM) is a late-stage pre-clinical company that has a solid cash position that enables the company to continue pushing ahead towards approval without needing to obtain new funding anytime soon…. As of March 31, 2022, the company had cash in the amount of just over $13 million! The company also [added $16.8 million to that through a sale of common stock and warrants in a private placement.]( (NASDAQ: SBFM) estimates they have enough cash on hand to fund operations for at least the next 24 months—a cushion that is quite attractive in this market environment and a big reason to keep the company on your radar! With exciting drug candidates for the massive oncology market and to fight the Covid-19 pandemic, as well as a solid balance sheet, NASDAQ: SBFM may soon capture major Wall Street attention! [Image] []( Sunshine Biopharma Inc. NASDAQ: SBFM Working to Change the Cancer Fight! Sunshine Biopharma (NASDAQ: SBFM) is a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs. The company has already shown good progress in creating a cancer-fighting drug that would, if approved, likely be a game changer in the cancer-fighting world! Additionally, the company is making progress on a Covid-19 treatment that attacks the virus in a different way—and may have implications beyond the current epidemic. The Portfolio SBFM’s ‘flagship anticancer compound is Adva-27a, a GEM-difluorinated C-glycoside derivative of Podophyllotoxin, that is targeted for various forms of cancer. The most important work the company is doing is the development of Adva-27a… Adva-27a is expected to enter Phase I clinical trials for pancreatic cancer and multidrug resistant breast cancer following completion of the GMP manufacturing and formulation of a 2-kilograms quantity for injection. The mechanism by which Adva-27a is able to destroy cancer cells is through the inhibition of a key cell-cycle enzyme called Topoisomerase II. Unlike other antitumor drugs currently in use, Adva-27a is able to destroy multidrug resistant cancer cells! Adva-27a is very effective against multidrug resistant breast cancer cells, while Etoposide, another Topoisomerase II inhibitor, has no activity against this aggressive form of cancer. In other studies, Adva-27a showed cell killing activity in various other types of multidrug resistant cancer cells. Preclinical studies to date have shown that: - Adva-27a is effective at killing different types of multidrug resistant cancer cells, including: - Breast Cancer Cells (MCF-7/MDR) - Small Cell Lung Cancer Cells (H69AR) - Uterine Cancer (MES-SA/Dx5) - Pancreatic Cancer (Panc-1) - Adva-27a is unaffected by P-Glycoprotein, the enzyme responsible for making cancer cells resistant to anti-tumour drugs. - Adva-27a has excellent clearance time (half-life = 54 minutes), as indicated by human microsomes stability studies and pharmacokinetics data in rats. - Adva-27a clearance is independent of Cytochrome P450, a mechanism that is less likely to produce toxic intermediates. - Adva-27a is an excellent inhibitor of Topoisomerase II with an IC50 of only 13.7 micromolar (this number has recently been reduced to 1.44 micromolar as a result of resolving the two isomeric forms of Adva-27a). - Adva-27a has shown an excellent pharmacokinetic profile, as indicated by studies done in rats. - Adva-27a does not inhibit tubulin assembly. NASDAQ: SBFM is planning to conduct their clinical trials at McGill University’s Jewish General Hospital in Montreal, Canada. All aspects of the planned clinical trials in Canada will employ FDA standards at all levels. The company estimates that it will take approximately 18 to 24 months from start to finish. Following successful completion of Phase I clinical trials, it is likely that they will be required to make Adva-27a available to patients under the “compassionate-use” guidelines. FIGHTING CORONAVIRUS There may already be vaccines and treatments for Covid-19 available, but an additional virus fighter doesn’t hurt anything and NASDAQ: SBFM is focused on an entirely different part of the virus… Coronavirus, a highly aggressive pathogen! Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of COVID-19, the ongoing pandemic that has claimed the lives of over 5.4 million people worldwide since it first appeared in December 2019. SARS-CoV-2 is a Betacoronavirus, one of four genera of Coronaviruses belonging to the family, Coronaviridae. The Betacoronaviruses are comprised of three highly virulent strains, including (i) SARS-CoV, which appeared in 2002 with an associated mortality rate of 10 to 15 percent, (ii) MERS-CoV, which came on the seen in 2015, wielding a case-fatality rate of 34 to 37 percent, and (iii) SARS-CoV-2, the causative agent of the current pandemic (COVID-19) with a mortality rate of 2 to 3 percent. In addition to the main protease (Mpro), which is shared among all coronaviruses, the Betacoronaviruses have a second virus-encoded protease called papain-like protease (PLpro). These two proteases are responsible for cleaving the initial expression products of the viral genome (polyproteins 1a and 1ab) at 15 different sites to produce 16 other mature virus proteins essential for viral replication. While Mpro cleaves the viral polyproteins 1a and 1ab at 12 different locations, PLpro cleaves polyprotein 1a at only 3 sites. PLpro is also involved in cleaving specific host proteins (various ubiquitinated proteins and ISG15), resulting in suppressing the host’s immune response. It is believed that PLpro is responsible for the enhanced pathogenicity of the Betacoronaviruses. NASDAQ: SBFM’s COVID-19 Treatment is an inhibitor of PLpro! The Company’s Covid-19 Treatment - On May 22, 2020, SBFM filed a patent application in the United States for a new treatment for Coronavirus infection. Their patent application covers composition subject matter pertaining to small molecules to inhibit the Coronavirus proteases. - In August 2020, the company completed the synthesis of four different potential inhibitors of Coronavirus protease. These compounds are based on the technology described in their patent application filed on May 22, 2020. - In September 2020, SBFM completed the screening of our four compounds and subsequently identified a lead Anti-Coronavirus drug candidate, SBFM-PL4. - SBFM recently expanded our research efforts into finding additional PLpro inhibitors by entering into a collaboration agreement with the University of Arizona. The collaboration is focused on determining in vivo safety, pharmacokinetics, dose selection, and mice efficacy studies of three University of Arizona owned PLpro inhibitors. The Company holds the first option to negotiate for a commercial, royalty-bearing license for all intellectual property developed by University of Arizona under the collaboration. This research being done has the potential to have wider ranging consequences that could be a benefit to both society and the company! The anti-viral drug market size is MASSIVE and is expected to reach [USD 50.02 BN by 2030]( due to the development of new, improved, and more advanced formulations. SBFM’s anticancer drugs are also an impressive feat. The company recently announced that it has filed a provisional patent application in the United States covering the recently communicated mRNA molecules found in pre-clinical trials to be effective at destroying cancer cells grown in culture. “We are excited about this potential intellectual property position we just staked in connection with our ongoing mRNA-as-therapeutic-agents research. We believe the potential use of mRNA to treat human diseases opens the door to vast therapeutic possibilities for patients.” --Dr. Steve Slilaty, CEO The oncology market size is expected to be worth around [US$ 536.01 billion by 2029]( from valued at USD 286.04 billion in 2021 and growing at a CAGR of 8.2% from 2021 to 2030! The company also has developed nutritional supplements which are for sale in Canada and the US on Amazon. The global dietary supplements market size was valued at [USD 151.9 billion in 2021]( and is expected to expand at a compound annual growth rate (CAGR) of 8.9% from 2022 to 2030. Just a few months ago, NASDAQ: SBFM reported exciting and successful results of their mRNA molecules and their ability to destroy cancer cells grown in culture, this skyrocketed their shares and just goes to show this company may have an exciting future ahead… Start your research as Sunshine Biopharma Inc. (NASDAQ: SBFM) has an exciting portfolio of treatments that could be medical game-changers on a variety of fronts! Disclaimer: This Newsletter/Website provides information about the stock market and other investments. This Newsletter/Website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This Newsletter/Website is for informational purposes only. The Author of this Newsletter/Website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Copyright 2022 © [TopStockTips.com]( is 50% owned and operated by the owner of CareBear Marketing Group LLC. Disclaimer and Privacy For more Information please contact Support@TopStockTips.com Company Address: 26 Downing Street, Newark NJ 07105. This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security. CareBear Marketing Group, its managers, its employees, affiliates, and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. To the maximum extent permitted by law, the Company disclaims all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete, or unreliable, or result in any investment or other losses. You received this message as part of your subscription to TST. TST is a free financial news and information website. We do not directly sell any products or offer any personal financial advice, nor do we advocate the purchase or sale of any security or investment for any specific individual. We also do not make any guarantee or warranty about what is advertised above. If you have questions or concerns about a product you’ve seen in one of our emails, we encourage you to reach out to that company directly. Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by CareBear Marketing Group. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “TST” refers to CareBear Marketing Group. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares, we will list the information relevant to the stock and the number of shares here. We do not own any shares in SBFM. We have been compensated Seventy-Five Thousand Dollars Cash ($75,000) via bank wire transfer from a third-party Open Market Media Group LLC for a 3 Day Marketing Program regarding SBFM with a start date of 7/26/2022 to 7/28/2022. TST’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding our alerts. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, TST often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. 18 R. Frei Tomé de Jesus Lisboa Lisboa 1700 PORTUGAL [Unsubscribe]( | [Change Subscriber Options](